primary progressive multiple sclerosis
Neurology · 2017–2020
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ocrelizumab Treatment of early, active primary progressive multiple sclerosis (PPMS) diagnosed within the previous 5 years with evidence of active inflammatory disease in… | Jul 2020 | Not recommended | 9 individuals MS Australia · MS Research Australia |
| ocrelizumab Treatment of primary progressive multiple sclerosis (PPMS) to delay the progression of physical disability. | Nov 2017 | Not recommended | 63 individuals MS Australia · MS Research Australia |
Who spoke
MS Australia · MS Research Australia
What the PBS pays
$249M in government benefit over 2024–25, across 15,188 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| ocrelizumab | $248.8M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| ocrelizumabOcrelizumab for treating primary progressive multiple sclerosis | TA585 | recommended restricted | 2019-06 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.